QQQ   390.19 (+0.26%)
AAPL   190.40 (+0.32%)
MSFT   382.70 (+1.08%)
META   338.99 (+1.28%)
GOOGL   137.20 (+0.58%)
AMZN   147.03 (-0.47%)
TSLA   246.72 (+4.51%)
NVDA   478.21 (-0.87%)
NIO   7.21 (+0.28%)
BABA   76.72 (-1.04%)
AMD   122.01 (-0.52%)
T   16.18 (-0.19%)
F   10.39 (+0.48%)
MU   76.12 (-1.79%)
CGC   0.54 (-1.82%)
GE   118.85 (-0.93%)
DIS   92.50 (-2.81%)
AMC   6.70 (-1.47%)
PFE   29.69 (-1.49%)
PYPL   58.47 (+3.69%)
XOM   103.90 (-0.06%)
QQQ   390.19 (+0.26%)
AAPL   190.40 (+0.32%)
MSFT   382.70 (+1.08%)
META   338.99 (+1.28%)
GOOGL   137.20 (+0.58%)
AMZN   147.03 (-0.47%)
TSLA   246.72 (+4.51%)
NVDA   478.21 (-0.87%)
NIO   7.21 (+0.28%)
BABA   76.72 (-1.04%)
AMD   122.01 (-0.52%)
T   16.18 (-0.19%)
F   10.39 (+0.48%)
MU   76.12 (-1.79%)
CGC   0.54 (-1.82%)
GE   118.85 (-0.93%)
DIS   92.50 (-2.81%)
AMC   6.70 (-1.47%)
PFE   29.69 (-1.49%)
PYPL   58.47 (+3.69%)
XOM   103.90 (-0.06%)
QQQ   390.19 (+0.26%)
AAPL   190.40 (+0.32%)
MSFT   382.70 (+1.08%)
META   338.99 (+1.28%)
GOOGL   137.20 (+0.58%)
AMZN   147.03 (-0.47%)
TSLA   246.72 (+4.51%)
NVDA   478.21 (-0.87%)
NIO   7.21 (+0.28%)
BABA   76.72 (-1.04%)
AMD   122.01 (-0.52%)
T   16.18 (-0.19%)
F   10.39 (+0.48%)
MU   76.12 (-1.79%)
CGC   0.54 (-1.82%)
GE   118.85 (-0.93%)
DIS   92.50 (-2.81%)
AMC   6.70 (-1.47%)
PFE   29.69 (-1.49%)
PYPL   58.47 (+3.69%)
XOM   103.90 (-0.06%)
QQQ   390.19 (+0.26%)
AAPL   190.40 (+0.32%)
MSFT   382.70 (+1.08%)
META   338.99 (+1.28%)
GOOGL   137.20 (+0.58%)
AMZN   147.03 (-0.47%)
TSLA   246.72 (+4.51%)
NVDA   478.21 (-0.87%)
NIO   7.21 (+0.28%)
BABA   76.72 (-1.04%)
AMD   122.01 (-0.52%)
T   16.18 (-0.19%)
F   10.39 (+0.48%)
MU   76.12 (-1.79%)
CGC   0.54 (-1.82%)
GE   118.85 (-0.93%)
DIS   92.50 (-2.81%)
AMC   6.70 (-1.47%)
PFE   29.69 (-1.49%)
PYPL   58.47 (+3.69%)
XOM   103.90 (-0.06%)

Sangamo Therapeutics Stock Price, News & Analysis (NASDAQ:SGMO)

$0.39
+0.02 (+5.38%)
(As of 11/28/2023 ET)
Compare
Today's Range
$0.36
$0.40
50-Day Range
$0.30
$0.85
52-Week Range
$0.29
$3.76
Volume
921,835 shs
Average Volume
2.02 million shs
Market Capitalization
$69.47 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.68

Sangamo Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Hold
2.29 Rating Score
Upside/​Downside
1,093.5% Upside
$4.68 Price Target
Short Interest
Healthy
5.81% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.62mentions of Sangamo Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$3 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.82) to ($0.53) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.19 out of 5 stars

Medical Sector

382nd out of 949 stocks

Biological Products, Except Diagnostic Industry

61st out of 161 stocks


SGMO stock logo

About Sangamo Therapeutics Stock (NASDAQ:SGMO)

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Brisbane, California.

SGMO Stock Price History

SGMO Stock News Headlines

Secure your stake in the Smart Home industry.
Last chance to invest in RYSE – the shade automation technology launching in over 100 Best Buy stores this month.
Where Sangamo Therapeutics Stands With Analysts
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity
Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
What 8 Analyst Ratings Have To Say About Sangamo Therapeutics
What To Know About RBC Capital's Downgrade of Sangamo Therapeutics
Sangamo Therapeutics earnings preview: what Wall Street is expecting
See More Headlines
Receive SGMO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sangamo Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/01/2023
Today
11/28/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/28/2024

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:SGMO
CUSIP
80067710
Employees
478
Year Founded
1995

Price Target and Rating

Average Stock Price Target
$4.68
High Stock Price Target
$10.00
Low Stock Price Target
$1.00
Potential Upside/Downside
+1,093.5%
Consensus Rating
Hold
Rating Score (0-4)
2.29
Research Coverage
7 Analysts

Profitability

Net Income
$-192,280,000.00
Net Margins
-123.88%
Pretax Margin
-126.13%

Debt

Sales & Book Value

Annual Sales
$111.30 million
Book Value
$1.80 per share

Miscellaneous

Free Float
172,027,000
Market Cap
$69.47 million
Optionable
Optionable
Beta
1.12

Social Links

10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Dr. Alexander D. Macrae Ch.B (Age 60)
    M.B., MRCP, Ph.D., CEO, President & Director
    Comp: $1.17M
  • Ms. Prathyusha Duraibabu CPA (Age 44)
    M.B.A., Senior VP, CFO & Principal Accounting Officer
    Comp: $628.08k
  • Mr. D. Mark McClung (Age 60)
    Executive VP & COO
    Comp: $710.3k
  • Dr. Jason D. Fontenot Ph.D. (Age 53)
    Senior VP & Chief Scientific Officer
    Comp: $682.76k
  • Phillip Ramsey
    Head of Technical Operations
  • Ms. Aron Feingold
    Head of Corporate Communications & Investor Relations Officer
  • Mr. Scott B. Willoughby (Age 48)
    Senior VP, General Counsel & Corporate Secretary
  • Ms. Whitney Jones
    Chief People Officer
  • Dr. Nathalie Dubois-Stringfellow Ph.D. (Age 61)
    Senior VP & Chief Development Officer
  • Dr. Lisa Rojkjaer M.D. (Age 57)
    Chief Medical Officer














SGMO Stock Analysis - Frequently Asked Questions

Should I buy or sell Sangamo Therapeutics stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Sangamo Therapeutics in the last twelve months. There are currently 1 sell rating, 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" SGMO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SGMO, but not buy additional shares or sell existing shares.
View SGMO analyst ratings
or view top-rated stocks.

What is Sangamo Therapeutics' stock price target for 2024?

7 brokers have issued 1 year price objectives for Sangamo Therapeutics' stock. Their SGMO share price targets range from $1.00 to $10.00. On average, they predict the company's stock price to reach $4.68 in the next twelve months. This suggests a possible upside of 1,093.5% from the stock's current price.
View analysts price targets for SGMO
or view top-rated stocks among Wall Street analysts.

How have SGMO shares performed in 2023?

Sangamo Therapeutics' stock was trading at $3.14 at the start of the year. Since then, SGMO shares have decreased by 87.5% and is now trading at $0.3917.
View the best growth stocks for 2023 here
.

When is Sangamo Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 28th 2024.
View our SGMO earnings forecast
.

How were Sangamo Therapeutics' earnings last quarter?

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) posted its quarterly earnings data on Wednesday, November, 1st. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.33) by $0.01. The biopharmaceutical company earned $9.40 million during the quarter, compared to analyst estimates of $10.17 million. Sangamo Therapeutics had a negative net margin of 123.88% and a negative trailing twelve-month return on equity of 61.40%.

What ETFs hold Sangamo Therapeutics' stock?

ETFs with the largest weight of Sangamo Therapeutics (NASDAQ:SGMO) stock in their portfolio include Kelly CRISPR & Gene Editing Technology ETF (XDNA) and Morningstar US Small Growth (MSGR).Global X Genomics & Biotechnology ETF (GNOM).

What is Sandy Macrae, M.B., Ch.B., Ph.D.'s approval rating as Sangamo Therapeutics' CEO?

10 employees have rated Sangamo Therapeutics Chief Executive Officer Sandy Macrae, M.B., Ch.B., Ph.D. on Glassdoor.com. Sandy Macrae, M.B., Ch.B., Ph.D. has an approval rating of 89% among the company's employees.

What other stocks do shareholders of Sangamo Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sangamo Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU), CRISPR Therapeutics (CRSP), Novavax (NVAX), Gilead Sciences (GILD), Brainstorm Cell Therapeutics (BCLI), Editas Medicine (EDIT), Netflix (NFLX) and Intel (INTC).

Who are Sangamo Therapeutics' major shareholders?

Sangamo Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Acadian Asset Management LLC (1.65%), Charles Schwab Investment Management Inc. (0.67%), UBS Group AG (0.42%), Mirae Asset Global Investments Co. Ltd. (0.38%), GSA Capital Partners LLP (0.32%) and Jacobs Levy Equity Management Inc. (0.23%). Insiders that own company stock include Biogen Inc, Gary Loeb, John Markels, Rolf Andrew Ramelmeier and Saira Ramasastry.
View institutional ownership trends
.

How do I buy shares of Sangamo Therapeutics?

Shares of SGMO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:SGMO) was last updated on 11/28/2023 by MarketBeat.com Staff

My Account -